checkAd
    Startseite > Aktien > Guardant Health > Nachrichten
    Guardant Health Aktie
    18,640
     
    USD
    -0,96 %
    -0,180 USD
    Letzter Kurs 02:00:00 Nasdaq
    18,650
     
    USD
    200 STK
    Geldkurs 08.05.24
    18,660
     
    USD
    2.800 STK
    Briefkurs 08.05.24
    ISIN: US40131M1099 · WKN: A2N5RY · SYM: GH · USA

    Neueste Nachrichten

    Guardant Health to Participate in Upcoming Investor Conferences
    07.05.24 · Business Wire (engl.) · Guardant Health
    Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone
    07.05.24 · Business Wire (engl.) · Guardant Health
    FDA Advisory Panel Review of Guardant Health’s Shield Blood Test to Screen for Colorectal Cancer to Be Held on May 23
    22.04.24 · Business Wire (engl.) · Guardant Health
    Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
    18.04.24 · Business Wire (engl.) · Guardant Health
    Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
    03.04.24 · Business Wire (engl.) · Guardant Health
    Fokus Aktien mit extremen Handelsvolumen am Donnerstag, den 28.03.2024
    28.03.24 · wO Chartvergleich · Energiekontor
    Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    06.03.24 · Business Wire (engl.) · Guardant Health
    New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap
    01.03.24 · Business Wire (engl.) · Guardant Health
    Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
    22.02.24 · Business Wire (engl.) · Guardant Health
    Guardant Health to Participate in Upcoming Investor Conferences
    15.02.24 · Business Wire (engl.) · Guardant Health
    Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
    01.02.24 · Business Wire (engl.) · Guardant Health
    Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence
    17.01.24 · Business Wire (engl.) · Guardant Health